Another piece in the puzzle

Over the past week I’ve been working on a new method of rapid reviews, one based on FDA regulatory documents [1, 2, 3].  In pursuing the reviews and their development I had a conversation with Kamal Mahtani (Deputy Director of the Centre for Evidence-Based Medicine) who asked if the FDA documents contained the data to undertake a meta-analysis.  Great question!  But I had no idea as I’ve never undertaken a systematic review and I hadn’t been looking for the data.  With the help of Erick Turner and a statistician colleague (thanks Mark) I located this table:

additional graph

And from that I was able (via statistician Mark) to get these two meta-analyses undertaken:

brex

The data was in such a format that to add this step might take the whole rapid review up to 60 minutes.  So, I think a good idea would be to take my initial review on Brexpiprazole [1] and update/edit it with Erick’s feedback [3] and the meta-analysis added.

We might then have a reasonably robust systematic review and meta-analysis of Brexpiprazole undertaken in an hour.

References

  1. Example rapid review: Brexpiprazole for schizophrenia
  2. Example rapid review: Empagliflozin in Type 2 Diabetes
  3. Example rapid review: Feedback from Erick Turner
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s